The registered record for TRAILRUNNER-ALZ 1 (ClinicalTrials.gov, NCT05463731), Eli Lilly's phase 3 study of the anti-amyloid antibody remternetug in early symptomatic Alzheimer's disease, now lists the study as completed, with an actual completion date of 12 May 2026. The same record gives a start date of 1 August 2022 and an actual primary completion date of 24 April 2024. As registered, the study is randomised, double-blind and placebo-controlled, with the drug or placebo given either by subcutaneous injection or by intravenous infusion over a 52 week main period, followed by an extension of up to 76 weeks, alongside an open-label addendum safety cohort of 974 further participants. Its primary outcome is the percentage of participants whose amyloid plaque is cleared, measured by PET. Eligibility, as registered, is ages 60 to 85, a Mini-Mental State Examination score of 20 to 30, an amyloid PET result meeting the trial's criteria, and a study partner in frequent contact with the participant.
The question that has drawn attention, whether people with Alzheimer's disease and their care partners can give the injection at home rather than attend an infusion chair, has been addressed so far in conference presentations rather than in a journal. The trade publication NeurologyLive reported in May 2026 that an analysis from TRAILRUNNER-ALZ 1 found subcutaneous self-injection to be practical, particularly at earlier stages. Dementias Today was not able to obtain the underlying presentation, and reports no figures from it here. The registration record itself documents only the route of administration, not who pushed the plunger.
In earlier disease, the successor study TRAILRUNNER-ALZ 3 (NCT06653153) began on 24 October 2024 and is registered as active and no longer recruiting, with estimated primary completion in April 2029 and study completion in October 2030. Lilly's own listing of its presentations at the Alzheimer's Association International Conference, held in London from 12 to 15 July 2026, includes a poster titled "Baseline Amyloid and Tau PET Characteristics in Early Alzheimer's Disease: Results from the TRAILRUNNER-ALZ 3 PET Addendum". The listing carries the title only; no baseline PET values appear in the public material, and Lilly's own announcement of its AAIC programme, a company press release, does not give them either.
The access argument that follows from a monthly injection is narrower than it may appear. Changing the route changes where a dose is given, not the confirmation of amyloid pathology before treatment, nor the MRI surveillance for amyloid-related imaging abnormalities that has accompanied this drug class. Remternetug is investigational and is not approved by any regulator. The registered primary endpoint of TRAILRUNNER-ALZ 1 is plaque clearance on a scan, a biomarker, not a measure of memory, thinking or daily function; the trial designed to test whether the drug delays clinical progression is TRAILRUNNER-ALZ 3, and by the sponsor's own estimate that answer is years away.